Medtronic PLC’s voluntary recall of its Valiant Navion thoracic stent graft system could cost the company up to $40m this quarter, execs estimated in a 23 February earnings call.
The recall, announced on 17 February, was spurred on by the death of a clinical trial participant, as well as other adverse or unexpected events
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?